Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Grant Revenue	$ 254,991	$ 161,842	$ 493,063	$ 366,867
Operating Expenses:
Research and development	472,927	434,214	1,028,462	982,607
General and administrative	576,918	527,831	706,720	966,676
Total Operating Expenses	1,049,845	962,045	1,735,182	1,949,283
Total Operating Loss	(794,854)	(800,203)	(1,242,119)	(1,582,416)
Other Income/(Expense):
Research and development tax credit	9,301	15,965	9,301	15,965
Interest expense	(61,295)	(50,824)	(118,072)	(96,065)
Total Other Expense, Net	(51,994)	(34,859)	(108,771)	(80,100)
Net Loss	$ (846,848)	$ (835,062)	$ (1,350,890)	$ (1,662,516)
Net Loss per share - basic	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Net Loss per share - diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of shares - basic	419,522,119	419,497,119	419,522,119	419,497,119
Weighted average number of shares - diluted	419,522,119	419,497,119	419,522,119	419,497,119